HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Mutant debrisoquine hydroxylation genes in Parkinson's disease.

Abstract
The frequency of fifteen genotypes of CYP2D6 (debrisoquine 4-hydroxylase) in 53 patients with Parkinson's disease was determined by the polymerase chain reaction (PCR) and restriction fragment length polymorphism (RFLP) analyses and compared with the findings in 72 healthy controls. The commonest mutant allele, CYP2D6B, was twice as frequent among patients as in controls, with an approximate relative risk ratio of 2.70 (95% confidence interval 1.14-6.41; p = 0.0063) for subjects homozygous or heterozygous for this allele.
AuthorsM Armstrong, A K Daly, S Cholerton, D N Bateman, J R Idle
JournalLancet (London, England) (Lancet) Vol. 339 Issue 8800 Pg. 1017-8 (Apr 25 1992) ISSN: 0140-6736 [Print] England
PMID1349052 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • Cytochrome P-450 Enzyme System
  • Mixed Function Oxygenases
  • Cytochrome P-450 CYP2D6
Topics
  • Aged
  • Alleles
  • Cytochrome P-450 CYP2D6
  • Cytochrome P-450 Enzyme System (genetics)
  • Female
  • Humans
  • Male
  • Mixed Function Oxygenases (genetics)
  • Mutation (genetics)
  • Parkinson Disease (genetics)
  • Polymerase Chain Reaction
  • Polymorphism, Restriction Fragment Length

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: